Skip to content

In the BioHarmony Drug Report Database

Alendronic acid

Binosto, Fosamax, Adrovance, Alendronate sodium and colecalciferol, MSD, Fosavance, Vantavo (alendronic acid) is a small molecule pharmaceutical. Alendronic acid was first approved as Binosto on 1995-09-29. It is used to treat extramammary paget disease and postmenopausal osteoporosis in the USA. It has been approved in Europe to treat postmenopausal osteoporosis. The pharmaceutical is active against farnesyl pyrophosphate synthase. Fosamax's patent is valid until 2031-12-05 (FDA).
Trade Name Adrovance, Alendronate sodium and colecalciferol, MSD, Fosavance, Vantavo
Common Name Alendronic acid
Indication extramammary paget disease, postmenopausal osteoporosis
Drug Class Calcium metabolism regulators
Alendronic acid
Get full access now